The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (BPMC) (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an ...

Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing ...

BeOne Medicines (ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early-stage trial to test a new cancer drug, BG-75098, in adults with advanced solid tumors.

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. On Wednesday, scientists reported interim results from an early study of ...

The UK's Medicines and Healthcare Products Agency (MHRA) has announced that it will soon launch a new regulatory program intended to allow severely ill consumers earlier access to potentially ...

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...